164 related articles for article (PubMed ID: 15827204)
1. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.
Daibata M; Bandobashi K; Kuroda M; Imai S; Miyoshi I; Taguchi H
J Virol; 2005 May; 79(9):5875-9. PubMed ID: 15827204
[TBL] [Abstract][Full Text] [Related]
2. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
Feng WH; Israel B; Raab-Traub N; Busson P; Kenney SC
Cancer Res; 2002 Mar; 62(6):1920-6. PubMed ID: 11912175
[TBL] [Abstract][Full Text] [Related]
4. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells.
Liu SF; Wang H; Lin XC; Xiang H; Deng XY; Li W; Tang M; Cao Y
Cell Biol Int; 2008 Aug; 32(8):1006-13. PubMed ID: 18579417
[TBL] [Abstract][Full Text] [Related]
6. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
Roychowdhury S; Peng R; Baiocchi RA; Bhatt D; Vourganti S; Grecula J; Gupta N; Eisenbeis CF; Nuovo GJ; Yang W; Schmalbrock P; Ferketich A; Moeschberger M; Porcu P; Barth RF; Caligiuri MA
Cancer Res; 2003 Mar; 63(5):965-71. PubMed ID: 12615710
[TBL] [Abstract][Full Text] [Related]
7. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
8. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
Mentzer SJ; Fingeroth J; Reilly JJ; Perrine SP; Faller DV
Blood Cells Mol Dis; 1998 Jun; 24(2):114-23. PubMed ID: 9628848
[TBL] [Abstract][Full Text] [Related]
9. A new compound, phomaherbarine A, induces cytolytic reactivation in epstein-barr virus-positive B cell lines.
Bae SE; Choi JW; Hong JW; Ku H; Sim KY; Ko GH; Jang DS; Shim SH; Park SG
Antiviral Res; 2024 Jul; 227():105906. PubMed ID: 38735576
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
11. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.
Ghosh SK; Forman LW; Akinsheye I; Perrine SP; Faller DV
Blood Cells Mol Dis; 2007; 38(1):57-65. PubMed ID: 17161633
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS.
Challine D; Buisson M; Cadilhac M; Germanidis G; Joab I; Eliaszewicz M; Caumes E; Flahault A; Fillet AM; Pawlotsky JM; Seigneurin JM
J Med Virol; 2002 Aug; 67(4):510-5. PubMed ID: 12115996
[TBL] [Abstract][Full Text] [Related]
13. Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
Suzuki T; Piche A; Kasono K; Xiang J; Gomez-Navarro J; Moriuchi S; Krisky DM; Oligino T; Glorioso JC; Curiel TJ; Curiel DT
Biochem Biophys Res Commun; 1998 Nov; 252(3):686-90. PubMed ID: 9837767
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in the treatment of EBV-positive low grade B-cell lymphoma.
Diamantopoulos PT; Polonyfi K; Sofotasiou M; Papadopoulou V; Kalala F; Iliakis T; Zervakis K; Tsilimidos G; Kouzis P; Kyrtsonis MC; Vassilakopoulos T; Angelopoulou M; Siakantaris M; Vayopoulos G; Kollia P; Pangalis G; Viniou NA
Anticancer Res; 2013 Dec; 33(12):5693-8. PubMed ID: 24324119
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.
Lee HG; Kim H; Kim EJ; Park PG; Dong SM; Choi TH; Kim H; Chong CR; Liu JO; Chen J; Ambinder RF; Hayward SD; Park JH; Lee JM
Oncotarget; 2015 Oct; 6(31):31018-29. PubMed ID: 26427042
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
19. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma.
Bossolasco S; Falk KI; Ponzoni M; Ceserani N; Crippa F; Lazzarin A; Linde A; Cinque P
Clin Infect Dis; 2006 Feb; 42(4):e21-5. PubMed ID: 16421782
[TBL] [Abstract][Full Text] [Related]
20. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.
Jones K; Nourse J; Corbett G; Gandhi MK
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e169-74. PubMed ID: 19196381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
